Entrada Therapeutics, Inc.
TRDAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Entrada Therapeutics, Inc. focuses on Biotechnology services and products. Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that. The $277.6M market capitalization puts TRDA squarely in micro-cap range for its industry. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Market Cap
$277.6M
Beta
-0.25
P/E (TTM)
—
P/E (Fwd)
-2.39
EPS (TTM)
$-3.96
EPS (Fwd)
$-2.98
ROE
-54.1%
ROA
-29.2%
Cash
$223.0M
Total Debt
$48.5M
Free CF
-$77.7M
52W Change
38.7%
Annual Financials
Cash vs Debt
Where TRDA stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, TRDA finished 25.79% below its 150-day moving average ($9.50) and 27.32% below its 200-day moving average ($9.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TRDA overbought or oversold?
At the September 1, 2026 close, TRDA's RSI(14) was 50.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Entrada Therapeutics, Inc. holds $223.0M in cash against $48.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$77.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -54.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.25 suggests TRDA is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TRDA.